Overview of FDA's Regulatory Framework for PET Drugs

Slides:



Advertisements
Similar presentations
Biopharmaceutical Quality
Advertisements

When is Excipient Reduced Testing Appropriate?
Regulatory Considerations for the Safety Assessment of Live Biotherapeutic Products in Clinical Trials Cara Fiore, Ph D US Food and Drug Administration.
Radiopharmaceutical Production
Dr. Raghuveer Pharma Consultants D R P C Quality. Perfection. Confidentiality. D R P C Quality. Perfection. Confidentiality. 1.
FDA’s Proposed Rule under FSMA for Preventive Controls
Assures that feed… –has the identity and strength, which it purports –meets the quality, purity, and safety requirements, which it is represented to possess.
GMP Document and Record Retention
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Transition to Inspections: USP, 21 CFR 212, And Beyond? Panel Discussion Ravi S. Harapanhalli, Ph.D Louis Marzella, MD Ravindra Kasliwal, Ph.D Wendy Sanhai,
Special Topics in IND Regulation
FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
Distributed Manufacturing via the SNM Multicenter FLT IND Part II SNM Midwinter Clinical Trials Network Albuquerque, New Mexico February 2, 2010 Sally.
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
Processing and Product Quality Issues Keith Wonnacott Ph.D. Office of Cellular, Tissue, and Gene Therapies E BC R Moving from Investigational to Licensed.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006.
1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.
DRUG MASTER FILES / 45.
Good Laboratory Practices (GLPs)
DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,
Regulatory Overview.
Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.
Overview of FDA's Regulatory Framework for PET Drugs
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
USFDA Canned Food Regulations Thermal Processing Deviations Registration and Process Filing William W. Deckert Jr.
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
Investigational New Drug Application (IND)
1 George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics Workings of the SNM Clinical Trials Network Centralized.
CBER HCT/P Contamination Prevention and Biologic Product Sterility Regulations Applicable to PBSCs Cell Therapy Liaison Meeting June 16, 2006 Ellen F.
Kimberly A. Trautman FDA’s Medical Device Quality System Expert
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
Proposed Regulations for Foreign Supplier Verification Programs (FSVPs)
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Proposed Rule for Preventive Controls for Animal Food.
Proposed Rule: 21 CFR 507 Proposed Rule for Preventive Controls for Animal Food 1.
1 2-Topic Imaging Workshop: (1)Standards for Imaging Endpoints in Clinical Trials (2) Manufacturing of PET Radiopharmaceutical Products Wendy R. Sanhai,
The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Large Multicenter Clinical Trials George.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Draft Guidance for Industry: CGMPs for Phase 1 INDs Joseph C. Famulare, Director Division of Manufacturing & Product Quality Office of Compliance, CDER,
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.
1 Imaging Community Critical Need #1: Standardized and Harmonized Multisite Imaging George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations.
Final Rule for Preventive Controls for Animal Food 1 THE FUTURE IS NOW.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Drug Development and IND Process GC 690 Walter Kraft, MD.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
Regulation of Generic Animal Drugs in the United States
FDA Draft Guidance on the Form FDA and Other Updates David A. Lepay, M.D., Ph.D. Senior Advisor for Clinical Science, U.S. FDA DIA GCP All-SIAC.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.
GOOD MANUFACTURING PRACTICE FOR BIOPROCESS ENGINEERING (ERT 425)
Formal Meetings between FDA and Sponsors of PDUFA Products
FDA 21 CFR Part 11 Overview June 10, 2006.
IND Review Process Seoul National University
Final Rule on Foreign Supplier Verification Programs
Radiopharmaceutical Production
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
Presentation transcript:

Overview of FDA's Regulatory Framework for PET Drugs Ravindra K. Kasliwal, Ph.D. Office of New Drug Quality Assessment Center for Drug Evaluation and Research U. S. Food and Drug Administration SNM June 2009

Background As mandated by Section 121(c)(1)(A) of FDAMA (1997), FDA has been developing CGMP regulations for PET drugs under 21 CFR 212 Concurrently, a guidance is being developed to help PET drug producers better understand FDA’s thinking regarding compliance with the new PET CGMP requirements SNM June 2009

Current Status Proposed CGMP regulations for PET drugs Federal Register: September 20, 2005 (Volume 70, Number 181), 55038 http://www.fda.gov/OHRMS/DOCKETS/98fr/05-18509.pdf Draft Guidance on CGMP for PET drugs Notice of availability - Federal Register: September 20, 2005 (Volume 70, Number 181), 55145 Draft guidance available at http://www.fda.gov/OHRMS/DOCKETS/98fr/98d-0266-gdl0002.pdf SNM June 2009

Current Status – Rule and Guidance The rule and guidance are not yet finalized and published by FDA FDA intends to finalize and publish the rule and guidance SNM June 2009

Current Status of PET Drugs Section 501(a)(2)(C) of the Federal Food, Drug, and Cosmetic Act (the Act): A compounded PET drug is adulterated unless it is produced in compliance with USP compounding standards (i.e., Chapter <823>) and the official monograph for the PET drug (i.e., USP monograph) SNM June 2009

Status of PET Drugs Section 501(a)(2)(C) will expire 2 years after the date on which FDA establishes approval procedures and CGMP requirements for PET drugs After which compliance with the PET CGMP regulations will be required SNM June 2009

Applicability of PET CGMP Regulations 21 CFR 212 -Current Thinking- Part 212 will apply to the production, quality control, holding and distribution of PET drugs Producers of investigational PET drugs and research PET drugs (for human administration) Option to follow the requirements in part 212 or to produce PET drugs in accordance with USP Chapter <823> SNM June 2009

Applicability of PET CGMP Regulations -Current Thinking- PET drugs, other than investigational and research PET drugs, must meet the regulatory requirements set forth in finalized 21 CFR 212 PET drugs marketed under an approved new drug application (NDA) or an approved abbreviated new drug application (ANDA) must be produced in accordance with the requirements in finalized 21 CFR 212 SNM June 2009

Proposed 21 CFR 212 Subpart A - General Provisions Subpart B - Personnel and Resources Subpart C - Quality Assurance Subpart D - Facilities and Equipment Subpart E - Control of Components, Containers, and Closures Subpart F - Production and Process Controls Subpart G - Laboratory Controls Subpart I - Packaging and Labeling Subpart J - Distribution Subpart K - Complaint Handling Subpart L - Records SNM June 2009

Laboratory Controls - Current Thinking Establish specifications for each PET drug product Critical quality attributes (CQA) that are indicative of product’s safety and effectiveness Before final release, conduct an appropriate laboratory determination to ensure that each batch of a PET drug product conforms to specifications, except for sterility Sterility is assured by process monitoring and controls, and confirmed by end product testing (sterility test should be started within 30 hours of end of production). SNM June 2009

Laboratory Controls - Current Thinking Appropriate laboratory determination could involve Finished product testing of each batch In-process testing of an attribute that is equivalent to the finished-product testing of that attribute Continuous process monitoring of one or more attributes with statistical process controls QbD, PAT Some combination of the above approaches Approach should be set forth in the product’s marketing application SNM June 2009

Non-Critical Quality Attributes Some product attributes may not be critical to the safety or efficacy of the product, but nevertheless are important in assessing the ongoing quality of the product and to assure that the manufacturing process is in control Radionuclidic purity (sometimes) Certain non-toxic solvents (Class 3 residual solvents) When justified, these could be tested as periodic quality indicator tests (PQIT) Performed at predetermined intervals rather than on a batch-to-batch basis Included in product's marketing application - listed separately from the specification Established and refined under firm's internal quality system SNM June 2009

Final Release - Current Thinking Final release can only occur after the completion of laboratory determination to ensure conformance to specifications (except for sterility) A product can be shipped under manufacturer’s control while certain tests are undergoing Results must be available and meet the acceptance criteria before final release is granted and the product is administered to a human subject SNM June 2009

Multicenter Clinical Trials of PET Radiopharmaceuticals -CMC Information / Data- File site-specific CMC information and data in the IND submitted by the sponsor PET drug producer provides complete information / data to the IND sponsor, who then submits this to the IND. File CMC information and data in DMF with FDA PET drug producer submits a DMF to the FDA Letter of Authorization (LOA) – DMF holder submits a copy with the DMF, sponsor files LOA with IND DMF must be filed with FDA before it is referenced in an application IND sponsor’s responsibility Must determine that products from different sites are equivalent Has overall responsibility for the conduct of research Must be in control of conduct of IND research at different sites SNM June 2009

IND Resources Regulations: 21 CFR 312 Guidance: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs http://www.fda.gov/cder/guidance/phase1.pdf INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information http://www.fda.gov/cder/guidance/3619fnl.pdf IND Meetings for Human Drugs and Biologics Chemistry, Manufacturing and controls Information http://www.fda.gov/cder/guidance/3683fnl.pdf SNM June 2009

Drug Master Files (DMF) Resources Guidance: Guideline for Drug Master Files http://www.fda.gov/cder/guidance/dmf.htm Send all comments or questions regarding DMFs to dmfquestion@cder.fda.gov. All inquiries MUST have an entry in the "Subject" field of the e-mail. Current DMF submission address: Food and Drug Administration Center for Drug Evaluation and Research Central Document Room 5901-B Ammendale Road Beltsville MD 20705-1266 SNM June 2009

New Drug CMC Questions? newdrugcmc@fda.hhs.gov Inquiries should have an entry in the "Subject" field of the e-mail indicating the subject of the question. SNM June 2009